Cisatracurium besylate lcarbamazine citrate 7 μg•hour/mL in HT1080 fibrosarcoma

7 μg•hour/mL in HT1080 fibrosarcoma model

It inhibits the interaction between β-catenin and T cell factor 4 (Tcf4) in quantitative reporter assays of β-catenin/Tcf4 binding (Ki = 53

[O-]C(=O)C1C=C(N=C2C=CC=CC2=1)C1C=C(C2=CC=CC=C2N=1)C([O-])=O

Quizartinib inhibits FLT3 with low nanomolar potency in cellular assays and is highly selective when screened against the majority of the human protein kinome

GW501516 exerts anti-inflammatory effects in mouse cultured proximal tubular (mProx) cells

Cisatracurium besylate lcarbamazine citrate 7 μg•hour/mL in HT1080 fibrosarcomaCisatracurium (formerly recognized as 51W89, and marketed as Nimbex) is a neuromuscular blocking drug or skeletal muscle relaxant in the category of non depolarizing neuromuscular blocking drugs, used adjunctively in anesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. It is a bisbenzyltetrahydroisoquinolinium agent with an intermediate duration of action. Cisatracurium is